MetaCap

Contineum Therapeutics (CTNM) vs Larimar Therapeutics (LRMR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Larimar Therapeutics (LRMR) has outperformed Contineum Therapeutics (CTNM) over the past year, losing 11.8% versus a loss of 20.7%. Contineum Therapeutics is the larger company by market cap ($340.8 million vs $328.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTNM-20.69%LRMR-11.80%
+73%+11%-50%
Nov 21, 20251 yearNov 20, 2026
CTNM-43.64%LRMR-57.80%
+47%-18%-83%
Apr 1, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTNM versus LRMR key metrics
MetricCTNMLRMR
Share price$8.68$3.14
Market cap$340.83M$328.55M
1-day change-3.98%-2.48%
YTD return-24.06%-17.59%
1-year return-20.69%-11.80%
5-year return—-68.97%
EPS (TTM)$-1.77$-1.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-59.98M$-165.67M
52-week high$17.79$6.42
52-week low$6.73$1.92
Distance from 52-week high-51.19%-51.09%
Analyst consensusbuystrong_buy
Avg. price target upside+146.89%+352.23%
Average volume776.03K1.38M
Shares outstanding35.35M104.63M
Employees5171
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Contineum Therapeutics

CTNM stock →

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

About Larimar Therapeutics

LRMR stock →

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees

CTNM vs LRMR FAQ

Which is bigger, Contineum Therapeutics or Larimar Therapeutics?

Contineum Therapeutics (CTNM) is larger, with a market capitalization of $340.83M compared with $328.55M for Larimar Therapeutics (LRMR).

Which stock has performed better over the past year, CTNM or LRMR?

LRMR returned -11.80% over the past 12 months, compared with -20.69% for CTNM (price return, excluding dividends). Past performance does not predict future results.

Are Contineum Therapeutics and Larimar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons